Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.55 |
| ▸ | CA2 | P00918 | 4/20 | 0.55 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.51 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.51 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | VDR | P11473 | 1/20 | 0.46 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23704697 | 1.00 | CA1 (0.55) | CA1CA2GPBAR1NR1H4TBXA2R | |
| SCHEMBL26426713 | 1.00 | CA1 (0.55) | CA1CA2GPBAR1NR1H4TBXA2R | |
| SCHEMBL26424229 | 0.96 | GPBAR1 (0.51) | CA1CA2GPBAR1NR1H4TBXA2R | |
| SCHEMBL26424224 | 0.90 | CA1 (0.64) | CA1CA2GPBAR1NR1H4TBXA2R | |
| SCHEMBL30103323 | 0.90 | CA1 (0.64) | CA1CA2GPBAR1NR1H4TBXA2R | |
| SCHEMBL26424218 | 0.90 | CA1 (0.64) | CA1CA2GPBAR1NR1H4TBXA2R | |
| SCHEMBL23710454 | 0.90 | GPBAR1 (0.57) | CA1CA2GPBAR1NR1H4TBXA2R | |
| SCHEMBL26426698 | 0.88 | GPBAR1 (0.58) | CA1CA2GPBAR1NR1H4TBXA2R | |
| SCHEMBL23710501 | 0.87 | CA1 (0.56) | CA1CA2GPBAR1NR1H4TBXA2R | |
| SCHEMBL23704681 | 0.87 | GPBAR1 (0.60) | CA1CA2GPBAR1NR1H4TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4097119-B1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES | UNIV JOHNS HOPKINS (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20230128984-A1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES, INCLUDING INFLAMMATORY BOWEL DISEASE (IBD) | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) | 2023-04-27 | — | — | US | disclosed |
| EP-4097119-A1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES | The Johns Hopkins University (US) | 2022-12-07 | — | — | EP | disclosed |
| WO-2021155167-A1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128984-A1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES, INCLUDING INFLAMMATORY BOWEL DISEASE (IBD) | SLC10A2, GPBAR1, NR1H4 | CA1 3966/4885CA2 2810/4885GPBAR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.